Ovid Therapeutics Inc (OVID) — Cash Flow-to-Debt Ratio
Ovid Therapeutics Inc (OVID) has a Cash Flow-to-Debt Ratio of -0.80x as of June 2026, meaning its operating cash flow of $-17.59 Million could theoretically repay -1% of its total liabilities ($22.08 Million) in one year. See Ovid Therapeutics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ovid Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Ovid Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Ovid Therapeutics Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Ovid Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Ovid Therapeutics Inc. Check cash flow quality index of Ovid Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.89x | $-38.33 Million | $20.27 Million | ▲ +19.1% |
| 2024 | -2.34x | $-55.96 Million | $23.94 Million | ▼ -187.1% |
| 2023 | -0.81x | $-45.78 Million | $56.23 Million | ▲ +66.1% |
| 2022 | -2.40x | $-55.23 Million | $22.99 Million | ▼ -130.0% |
| 2021 | 8.02x | $118.61 Million | $14.80 Million | ▲ +601.8% |
| 2020 | -1.60x | $-51.58 Million | $32.29 Million | ▲ +66.2% |
| 2019 | -4.72x | $-51.09 Million | $10.82 Million | ▲ +8.3% |
| 2018 | -5.15x | $-45.56 Million | $8.84 Million | ▲ +1.4% |
| 2017 | -5.23x | $-31.47 Million | $6.02 Million | ▼ -9.6% |
| 2016 | -4.77x | $-17.80 Million | $3.73 Million | ▼ -100.7% |
| 2015 | -2.38x | $-5.49 Million | $2.31 Million | ▼ -9.1% |
| 2014 | -2.18x | $-261.28K | $119.95K | — |